 Novartis AGs expectations for a new heartfailure drug suffered a second setback as a Food and Drug Administration staff review recommended against approval Earlier this year an advisory panel in Europe made a similar recommendation The FDAs medical review said the data didnt show serelaxin slowed progress of heart failure nor did it provide persuasive evidence of an effect on shortness of breath a main heartfailure symptom